



Elucid Bioimaging Inc.'s \$80 Million Series C Funding Round

Description

Honigman represented Elucid Bioimaging Inc. in the transaction, and Latham and Watkins represented Elevage Medical Technologies.

Elucid Bioimaging Inc. announced it has raised \$80 million in Series C financing round.

The round was led by Elevage Medical Technologies, with additional participation from industry strategics and existing investors. With this funding, Elucid is poised to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease. This round brings the company's total funding to \$121 million since inception.

Elucid is a Boston-based medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software is designed to understand the root cause of cardiovascular disease deeply.

Elevage Medical Technologies is a platform created by Patient Square Capital dedicated to supporting medical device and technology companies that can meaningfully improve health outcomes and quality of life for patients.

The Honigman team was led by corporate partners Phil Torrence (Picture) and John Hertel.

Involved fees earner: [John Hertel – Honigman LLP](#); [Phillip Torrence – Honigman LLP](#);

Law Firms: [Honigman LLP](#);

Clients: [Elucid Bioimaging Inc.](#);

Date Created

November 27, 2023

Author

leila-ahmed